Overview

Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CY

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of a chronic co-medication of efavirenz on pharmacokinetics and sterol-lowering effects of ezetimibe at steady-state in healthy subjects genotyped for ABCB1, ABCC2, CYP2B6 and UGT1A1.

Phase:

Phase 1

Details

Lead Sponsor:

University Medicine Greifswald

Treatments:

Efavirenz
Ezetimibe
Reverse Transcriptase Inhibitors